Abstract
This case series describes clinical characteristics, treatment, and outcomes of 17 previously healthy SARS-CoV-2–infected children and adolescents with an inflammatory phenotype overlapping with but distinct from Kawasaki disease and toxic shock syndrome admitted to a New York City hospital in late April and early May 2020.
Conflict of interest statement
Dr Orange reported receiving personal fees from ADMA Biologics, CSL Bhering, Gigagen, Grifols, and Takeda. No other disclosures were reported.
Comment in
-
SARS-CoV-2-Related Inflammatory Multisystem Syndrome in Children: Different or Shared Etiology and Pathophysiology as Kawasaki Disease?McCrindle BW, Manlhiot C. McCrindle BW, et al. JAMA. 2020 Jul 21;324(3):246-248. doi: 10.1001/jama.2020.10370. JAMA. 2020. PMID: 32511667 No abstract available.
References
-
- McCrindle BW, Rowley AH, Newburger JW, et al. ; American Heart Association Rheumatic Fever, Endocarditis, and Kawasaki Disease Committee of the Council on Cardiovascular Disease in the Young; Council on Cardiovascular and Stroke Nursing; Council on Cardiovascular Surgery and Anesthesia; and Council on Epidemiology and Prevention . Diagnosis, treatment, and long-term management of Kawasaki disease: a scientific statement for health professionals from the American Heart Association. Circulation. 2017;135(17):e927-e999. doi: 10.1161/CIR.0000000000000484 - DOI - PubMed
MeSH terms
Substances
Supplementary concepts
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous
